Sign in

Jose Antonio Meade

@josemeade.bsky.social
46 followers 164 following 23 posts

PCCM fellow @mayoclinic.org - Interests include but not limited to #POCUS, meded and autoimmunity #RheumCrit 🩺⚕️

PostsRepliesMedia
Jose Antonio Meade @josemeade.bsky.social · 30/06/2026
This is a reminder that science is self-correcting, and that patients deserve evidence they can trust.
010
Jose Antonio Meade @josemeade.bsky.social · 30/06/2026
The ADVOCATE retraction isn’t necessarily the end of avacopan, it is the end of relying on evidence that can no longer be trusted. A retracted trial doesn’t prove a drug is ineffective. It means we need better evidence.
110
Jose Antonio Meade @josemeade.bsky.social · 06/05/2026
Bradykinin is an amazing molecule. Intersection between inflammation cascade, coagulation cascade, complement system AND RAAS system! Imagen generated with GPT.
020
Jose Antonio Meade @josemeade.bsky.social · 15/04/2026
This was the first project I got involved during residency, thanks to the great @rheumcat.bsky.social and Dr. Rachael Stovall. I received outstanding mentorship from amazing researchers and rheumatologists from France and the U.S. #WomenInScience
130
Jose Antonio Meade @josemeade.bsky.social · 15/04/2026
Clinically, this is reassuring. Younger adults who have not had symptoms of axSpA for a long time can be counseled on the long term risks of taking higher, anti-inflammatory doses of NSAIDs. For many patients, this is a good option without needing to go on biologics.
110
Jose Antonio Meade @josemeade.bsky.social · 15/04/2026
Publication alert! 🚨 Does higher NSAID use increase the risk of incident hypertension in younger patients with newly diagnosed axSpA? Short answer: No. At least on the first 10 years of the disease course. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...
141
Reposted by Jose Antonio Meade
Matt Siuba @zentensivist.bsky.social · 23/03/2026
The success rate of “idk try an inotrope” has to be sub 5%* *even for intermediate physiologic outcomes
261
Jose Antonio Meade @josemeade.bsky.social · 26/03/2026
I am extremely grateful with @rheumcat.bsky.social for offering her time and mentorship with this project even before I started residency! It is a great clinical question with many implications and I learned many research skills from this!
041
Jose Antonio Meade @josemeade.bsky.social · 05/02/2026
I asked ChatGPT to do a cartoon of my work based on everything it knows about me… the more you look at it, the more accurate it is!
010
Jose Antonio Meade @josemeade.bsky.social · 04/02/2026
Beta-blockers (BB) continue to lose terrain in different specific clinical scenarios. Sounds like this old question is finally answered… Use of BB after MI with normal EF: nejm.org/doi/full/10.10…
010
Jose Antonio Meade @josemeade.bsky.social · 03/12/2025
Thank you for all your mentorship and support throughout!!! You are an amazing mentor and person!
010
Reposted by Jose Antonio Meade
Rheum Cat @rheumcat.bsky.social · 03/12/2025
My research mentee matched to Mayo Clinic Pulm Crit!! Sooo happy for @josemeade.bsky.social, congrats!! #Fellowship #Match #MatchDay
2191
Reposted by Jose Antonio Meade
Rheumatology Research Foundation @rheumresearch.bsky.social · 07/11/2025
📣 Calling all MD & DO students (including MD/PhD, DO/PhD, MD/MPH, DO/MPH)! Apply for the Rheumatology Future Physician Scientist Award, supporting research training for future physician-scientists in rheumatology. 🗓️ Applications due Dec 1, 2025 by 5 PM ET rheumresearch.org/preceptorships#RFPS
021
Reposted by Jose Antonio Meade
Rheum Cat @rheumcat.bsky.social · 27/10/2025
My first rheum research mentor who got me to my first ACR in 2016: Dr Jen Barton #ACR25
Jen Barton and Jean Liew in front of the former’s research poster at ACR25
1131
Reposted by Jose Antonio Meade
Alison Bays, MD (she/her) @alisonbays.bsky.social · 27/10/2025
Abstract 1604: anti-rituximab antibodies as a cause of treatment failure in ANCA & cryoglobulinemic vasculitis. #ACR25
043
Reposted by Jose Antonio Meade
Alison Bays, MD (she/her) @alisonbays.bsky.social · 27/10/2025
Malignancy association with Ro52 positivity. #ACR25
034
Reposted by Jose Antonio Meade
Tiffany @tiffanyandlupus.bsky.social · 27/10/2025
Dr. Martha Delgado gave a great #ACR25 presentation focused on improving patient participation in clinical trials in Latino communities. She shared barriers for both patients & providers as well current efforts to remove barriers. cc: @ladaorg.bsky.social #LADAorg @lupuschat.bsky.social #LupusChat
055
Reposted by Jose Antonio Meade
Rheum Cat @rheumcat.bsky.social · 27/10/2025
Cat interlude #ACR25
Black cat looks at camera
31908
Reposted by Jose Antonio Meade
Dan Lewer @danlewer.bsky.social · 27/10/2025
We wrote an article explaining why you shouldn't put several variables into a regression model and report which are statistically significant - even as exploratory research. bmjmedicine.bmj.com/content/4/1/.... How did we do?
A "methods primer" article in the journal "BMJ Medicine", titled "Factors associated with: problems of using exploratory multivariable regression to identify causal risk factors"
26275107
Jose Antonio Meade @josemeade.bsky.social · 23/10/2025
Today, in collaboration with @BUMedicine Emergency Medicine, we shared some basic POCUS skills to our second-year medical students. Let’s keep integrating POCUS into medical school curricula!
000
Reposted by Jose Antonio Meade
Irina Bezsonova @irinabezsonova.bsky.social · 14/10/2025
This October I’m drawing 1 molecule a day inspired by proteins in pdb @rcsbpdb.bsky.social Day 13 Prompt DRINK Pdb: 7BTW A pair of mitochondrial outer membrane β-barrel SAM complexes from Saccharomyces cerevisiae, the yeast used to make beer. Cheers! Next: TRUNK Suggestions?
2469
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
6️⃣ The big picture Early TNFi ≠ less opioid use. Future work should include pain scores, disease activity, and social factors to fully understand pain and opioid trajectories in axSpA. #Rheumatology #axSpA #Opioids #TNFi #Pharmacoepidemiology
acrjournals.onlinelibrary.wiley.com
The Effect of Early Tumor Necrosis Factor Inhibitor Initiation on Chronic Opioid Use in Individuals with Axial Spondylarthritis
Objective Opioid use remains common despite effective therapies for axial spondyloarthritis (axSpA). We assessed whether early tumor necrosis factor inhibitor (TNFi) use is associated with reduced r...
010
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
5️⃣ Why it matters 💡 Chronic opioid use is still common (~21%) in axSpA 💥 Biologic therapy alone may not solve the opioid problem 🧠 Need multimodal, holistic pain strategies
110
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
4️⃣ Takeaway ❌ Early TNFi use did not reduce opioid use. 📈 In opioid-naïve patients, it was linked to higher chronic use. Likely due to confounding by indication — patients with worse disease start TNFi earlier and need more pain control.
110
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
3️⃣ Results 8,508 matched individuals (mean age 42, 50% women). 💊 Chronic opioid use in 20.9% overall. ⚠️ Early TNFi = higher risk (HR 1.17, 95% CI 1.06–1.28). Opioid-naïve: HR 1.96 🚨 Opioid-experienced: NS
110
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
2️⃣ Methods 🧾 MarketScan® claims data (US) 👥 Adults 18–65 with new axSpA ⚕️ “Early TNFi” = started ≤6 months after diagnosis 📊 Propensity score–matched 1:1 💊 Outcome: chronic opioid use ≥90 days
110
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
1️⃣ Background Opioid use remains high in axSpA — even with effective biologics like TNFi. We asked: could starting TNFi early lower the risk of chronic opioid use?
110
Jose Antonio Meade @josemeade.bsky.social · 14/10/2025
🧵 New study alert! 💊 Does early TNF inhibitor (TNFi) therapy reduce chronic opioid use in axial spondyloarthritis (axSpA)? 👉 We looked at real-world US data to find out. 📄 Arthritis Care & Research, 2025 🔗 acrjournals.onlinelibrary.wiley.com/doi/10.1002/... @rheumcat.bsky.social
252
Reposted by Jose Antonio Meade
Rheum Cat @rheumcat.bsky.social · 18/11/2024
Proud mentor of Dr. Jose Meade-Aguilar (BU/BMC internal medicine resident) #ACR24
111
Reposted by Jose Antonio Meade
Rheum Cat @rheumcat.bsky.social · 10/12/2024
Thanks for the head's up @restovall.bsky.social! Our mentee Jose Meade-Aguilar's work is cited from #ACR24 here: www.the-rheumatologist.org/article/key-...
the-rheumatologist.org
Key Research in Axial Spondyloarthritis Encapsulated - The Rheumatologist
Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize...
098
Reposted by Jose Antonio Meade
ACR Journals @acr-journals.bsky.social · 06/09/2025
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN) 🎙️Listen → acr.tw/3UWKCXi #Medsky
ACR Journals on Air podcast banner
132
Jose Antonio Meade @josemeade.bsky.social · 25/09/2025
Wait you also moved! @rheumcat.bsky.social
000
Jose Antonio Meade @josemeade.bsky.social · 25/09/2025
They moved :(
100
Jose Antonio Meade @josemeade.bsky.social · 25/09/2025
We had so much fun sharing some Lung POCUS basics to our MS2s @bumedicine.bsky.social! Their names is Ultrasound Is for Everyone and I just love it.
000
Jose Antonio Meade @josemeade.bsky.social · 15/05/2025
Thank you @rheumcat.bsky.social for many hours of outstanding mentoring and hard work! What an incredible journey this has been! @rheumresearch.bsky.social
020
Jose Antonio Meade @josemeade.bsky.social · 12/11/2024
I am here basically because @rheumcat.bsky.social
020